Filtered By:
Condition: Congestive Heart Failure
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 1952 results found since Jan 2013.
Major Adverse Cardiovascular Events in Korean Congenital Heart Disease Patients: A Nationwide Age- and Sex-Matched Case-Control Study
CONCLUSION: In conclusion, this nationwide study demonstrates that Korean patients with CHD have a high incidence of comorbidities, vascular events, and mortality. CHD has been established as an important predictor of cardiovascular events. Further studies are warranted to identify high-risk patients with CHD and related factors to prevent vascular events.PMID:36444542 | PMC:PMC9760894 | DOI:10.3349/ymj.2022.0111
Source: Yonsei Medical Journal - November 29, 2022 Category: Universities & Medical Training Authors: Jue Seong Lee Jin-Man Jung Jongun Choi Woo-Keun Seo Hong Ju Shin Source Type: research
Safety and Efficacy of Rivaroxaban, Apixaban, and Dabigatran in Obese and Morbidly Obese Patients with Heart Failure and Atrial Fibrillation: A Real ‐World Analysis
ConclusionIn obese patients with congestive heart failure and atrial fibrillation or atrial flutter on DOACs, apixaban has the most favorable safety profile compared to rivaroxaban and dabigatran.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - November 24, 2022 Category: Cardiology Authors: Yashasvi Chugh,
Kashvi Gupta,
Hanumanthu Balram Krishna,
Renato Quispe Ayala,
Ignacio Zepeda,
Michael Grushko,
Robert T Faillace Tags: ORIGINAL ARTICLE Source Type: research
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease
CONCLUSIONS: We found there is probably little to no difference in total mortality and cardiovascular mortality between people with hypertension and cardiovascular disease treated to a lower compared to a standard blood pressure target. There may also be little to no difference in serious adverse events or total cardiovascular events. This suggests that no net health benefit is derived from a lower systolic blood pressure target. We found very limited evidence on withdrawals due to adverse effects, which led to high uncertainty. At present, evidence is insufficient to justify lower blood pressure targets (135/85 mmHg or le...
Source: Cochrane Database of Systematic Reviews - November 18, 2022 Category: General Medicine Authors: Luis Carlos Saiz Javier Gorricho Javier Garj ón M ª Concepción Celaya Juan Erviti Leire Leache Source Type: research
Outcomes of Carotid Stenting in Patients with Fibromuscular Dysplasia
CONCLUSION: Carotid artery stenting for fibromuscular dysplasia is a feasible and safe procedure with favorable technical success, low neurological complications, and good clinical outcomes at 1-year follow-up.PMID:36400362 | DOI:10.1016/j.jvs.2022.10.040
Source: Atherosclerosis - November 18, 2022 Category: Cardiology Authors: Jesus Porras-Colon Carla K Scott Alejandro Pizano Anna Driessen Carlos H Timaran John G Modrall Shirling Tsai Melissa L Kirkwood Bala Ramanan Source Type: research
Application of computed tomographic angiography and echocardiography in predicting left atrial appendage thrombosis in patients with non-valvular atrial fibrillation
CONCLUSIONS: Both CTA and RT-3D-TEE had high predictive values for LAA thrombosis in atrial fibrillation patients.PMID:36383152 | DOI:10.5830/CVJA-2022-052
Source: Cardiovascular Journal of Africa - November 16, 2022 Category: Cardiology Authors: Xiaodan Wu Fan Sun Shoucheng Ma Zhichen Wang Shenghai Xu Source Type: research
